AR065799A1 - Moduladores cannabinoides hexahidrocicloheptapirazol - Google Patents
Moduladores cannabinoides hexahidrocicloheptapirazolInfo
- Publication number
- AR065799A1 AR065799A1 ARP080101147A ARP080101147A AR065799A1 AR 065799 A1 AR065799 A1 AR 065799A1 AR P080101147 A ARP080101147 A AR P080101147A AR P080101147 A ARP080101147 A AR P080101147A AR 065799 A1 AR065799 A1 AR 065799A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydroxy
- halogen
- positions
- optionally substituted
- alkyl
- Prior art date
Links
- 229930003827 cannabinoid Natural products 0.000 title 1
- 239000003557 cannabinoid Substances 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 28
- 150000002367 halogens Chemical class 0.000 abstract 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 28
- 125000003545 alkoxy group Chemical group 0.000 abstract 20
- 125000000217 alkyl group Chemical group 0.000 abstract 17
- 125000003118 aryl group Chemical group 0.000 abstract 16
- 125000000623 heterocyclic group Chemical group 0.000 abstract 15
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 abstract 11
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000002947 alkylene group Chemical group 0.000 abstract 6
- 125000004043 oxo group Chemical group O=* 0.000 abstract 6
- 150000002431 hydrogen Chemical group 0.000 abstract 5
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 4
- 125000004104 aryloxy group Chemical group 0.000 abstract 4
- 125000005242 carbamoyl alkyl group Chemical group 0.000 abstract 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 4
- 125000005102 carbonylalkoxy group Chemical group 0.000 abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 abstract 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 3
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- -1 lower-amino alkyl Chemical group 0.000 abstract 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108050007331 Cannabinoid receptor Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000001118 alkylidene group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000028774 intestinal disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
Estos compuestos son utiles para tratar, mejorar o prevenir un síndrome, trastorno o enfermedad mediado por el receptor cannabinoide, tales como obesidad, trastornos metabolicos, enfermedades intestinales e infarto de miocardio. Reivindicacion 1:Un compuesto que tiene una estructura de acuerdo con la formula (1), o una sal, isomero, profármaco, metabolito o polimorfo del mismo donde las líneas discontinuas entre las posiciones 2-3 y posiciones 3a-8a en la formula (1) representan ubicacionespara cada uno de los dos dobles enlaces presentes cuando X1R1 está presente; las líneas discontinuas entre las posiciones 3-3a y posiciones 8a-1 en formula (1) representan ubicaciones para cada uno de los dos dobles enlaces presentes cuando X2R2está presente; la línea discontinua entre la posicion 8 y X4R4 en la formula (1) representa una ubicacion para un doble enlace; X1 está ausente o es alquileno inferior; X2 está ausente o es alquileno inferior; donde solo uno de X1R1 y X2R2 estánpresentes; X3 está ausente, es alquileno inferior, alquilideno inferior o -NH-; cuando la línea discontinua entre la posicion 8 y X4R4 está ausente, X4 está ausente, o es alquileno inferior, cuando la línea discontinua entre la posicion 8 y X4R4está presente, X4 está ausente; X5 está ausente o es alquileno inferior; R1 se selecciona entre hidrogeno, alquilo (opcionalmente sustituido en una o más posiciones con halogeno, hidroxi o alcoxi inferior), alquilo inferior-sulfonilo, arilo,cicloalquilo C3-12 o heterociclilo, donde cada arilo, cicloalquilo C3-12 o heterociclilo está opcionalmente sustituido en una o más posiciones con halogeno, aminosulfonilo, alquilo inferior-aminosulfonilo, alquilo (opcionalmente sustituido en una omás posiciones con halogeno, hidroxi o alcoxi inferior), hidroxi o alcoxi inferior (opcionalmente sustituido en una o más posiciones con halogeno o hidroxi); R2 se selecciona entre hidrogeno, alquilo (opcionalmente sustituido en una o más posicionescon halogeno, hidroxi o alcoxi inferior), alquilo inferior-sulfonilo, arilo, cicloalquilo C3-12 o heterociclilo, donde cada arilo, cicloalquilo C3-12 o heterociclilo está opcionalmente sustituido en una o más posiciones con halogeno, aminosulfonilo,alquilo inferior-aminosulfonilo, alquilo (opcionalmente sustituido en una o más posiciones con halogeno, hidroxi o alcoxi inferior), hidroxi o alcoxi inferior (opcionalmente sustituido en una o más posiciones con halogeno o hidroxi); R3 es -C(O)-Z1(R6), -SO2-NR7-Z2(R8) o -C(O)-NR9-Z3(R10); cuando la línea discontinua entre la posicion 8 y X4R4 está ausente, X4 está ausente o es alquileno inferior y R4 es hidroxi, alquilo inferior, alcoxi inferior, halogeno, arilo, cicloalquilo C3-12 oheterociclilo, donde cada arilo, cicloalquilo C3-12 o heterociclilo está opcionalmente sustituido en una o más posiciones con hidroxi, oxo, alquilo inferior (opcionalmente sustituido en una o más posiciones con halogeno, hidroxi o alcoxi inferior),alcoxi inferior (opcionalmente sustituido en una o más posiciones con halogeno o hidroxi) o halogeno; cuando la línea discontinua entre la posicion 8 y X4R4 está presente, X4. está ausente y R4, es CH-arilo o CH-heterociclilo, donde cada arilo oheterociclilo está opcionalmente sustituido en una o más posiciones con hidroxi, oxo, alquilo inferior (opcionalmente sustituido en una o más posiciones con halogeno, hidroxi o alcoxi inferior), alcoxi inferior (opcionalmente sustituido en una o másposiciones con halogeno o hidroxi) o halogeno; R5 es hidrogeno, hidroxi, oxo, halogeno, amino, alquilo inferior-amino, alquilo (opcionalmente sustituido en una o más posiciones con halogeno, hidroxi o alcoxi inferior), alcoxi inferior (opcionalmentesustituido en una o más posiciones con halogeno o hidroxi), carboxi carbonilalcoxi, carbamoilo, carbamoilalquilo, arilo, ariloxi, arilalcoxi o heterociclilo; R6 es arilo, cicloalquilo C3-12 o heterociclilo cada uno opcionalmente sustituido con uno omás hidroxi, oxo, halogeno, amino, alquilo inferior-amino, alquilo (opcionalmente sustituido en una o más posiciones con halogeno, hidroxi o alcoxi inferior), alcoxi inferior (opcionalmente sustituido en una o más posiciones con halogeno o hidroxi),carboxi, carbonilalcoxi, carbamoilo, carbamoilalquilo, arilo, ariloxi, arilalcoxi o heterociclilo; R7 es hidrogeno o alquilo inferior; R8 es hidrogeno, arilo, cicloalquilo C3-12 o heterociclilo, donde arilo, cicloalquilo C3-12 o heterociclilo estáncada uno opcionalmente sustituido con uno o más hidroxi, oxo, halogeno, amino, alquilo inferior-amino, alquilo (opcionalmente sustituido en una o más posiciones con halogeno, hidroxi o alcoxi inferior), alcoxi inferior (opcionalmente sustituido enuna o más posiciones con halogeno o hidroxi), carboxi, carbonilalcoxi, carbamoilo, carbamoilalquilo, arilo, ariloxi, arilalcoxi o heterociclilo; R9 es hidrogeno o alquilo inferior; R10 es hidrogeno, arilo, cicloalquilo C3-12 o heterociclilo, dondecada arilo, cicloalquilo C3-12 o heterociclilo está opcionalmente sustituido con uno o más hidroxi, oxo, halogeno, amino, alquilo inferior-amino, alquilo (opcionalmente sustituido en una o más posiciones con halogeno, hidroxi o alcoxi inferior),alcoxi inferior (opcionalmente sustituido en una o más posiciones con halogeno o hidroxi), carboxi, carbonilalcoxi, carbamoilo, carbamoilalquilo, aminosulfonilo, alquilo inferior-aminosulfonilo, arilo, ariloxi, arilalcoxi o heterociclilo; Z1 y Z2están ausentes o son alquilo; y Z3 está ausente, -NH-, -SO2- o alquilo (donde alquilo está opcionalmente sustituido en una o más posiciones con halogeno, hidroxi, alquilo inferior, alcoxi inferior, carboxi o carbonilalcoxi).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/688,552 US8378117B2 (en) | 2005-09-23 | 2007-03-20 | Hexahydro-cycloheptapyrazole cannabinoid modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065799A1 true AR065799A1 (es) | 2009-07-01 |
Family
ID=39189452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101147A AR065799A1 (es) | 2007-03-20 | 2008-03-19 | Moduladores cannabinoides hexahidrocicloheptapirazol |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8378117B2 (es) |
| EP (1) | EP2139328A4 (es) |
| JP (1) | JP2010529949A (es) |
| KR (1) | KR20100015602A (es) |
| CN (1) | CN101677557A (es) |
| AR (1) | AR065799A1 (es) |
| AU (1) | AU2008229202A1 (es) |
| BR (1) | BRPI0809037A2 (es) |
| CA (1) | CA2681468A1 (es) |
| CL (1) | CL2008000799A1 (es) |
| CO (1) | CO6220909A2 (es) |
| IL (1) | IL200957A0 (es) |
| MX (1) | MX2009010157A (es) |
| NZ (1) | NZ579649A (es) |
| PE (1) | PE20090061A1 (es) |
| TW (1) | TW200901976A (es) |
| UA (1) | UA98487C2 (es) |
| WO (1) | WO2008115705A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009010162A (es) * | 2007-03-21 | 2009-10-12 | Janssen Pharmaceutica Nv | Metodo para tratar dolor mediado por el receptor cb2. |
| CN102282147B (zh) * | 2009-01-28 | 2015-09-30 | 卡拉治疗学股份有限公司 | 二环吡唑并-杂环 |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物 |
| WO2022132545A1 (en) * | 2020-12-15 | 2022-06-23 | Merck Sharp & Dohme Corp. | Fused [7,5] bicyclic pyrazole derivatives and methods of use thereof for the treatment of herpesviruses |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2948718A (en) | 1960-08-09 | New n-heterocyclic compounds | ||
| DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4087544A (en) | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| ZW12980A1 (en) | 1979-06-01 | 1982-01-06 | Wellcome Found | Substituted aromatic compounds |
| LU83729A1 (fr) | 1981-11-04 | 1983-09-01 | Galephar | Sels d'acide valproique,leur preparation et leur utilisation |
| US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
| US5164381A (en) | 1986-05-29 | 1992-11-17 | Ortho Pharmaceutical Corporation | Pharmacologically active 1,5-diaryl-3-substituted pyrazoles and method for synthesizing the same |
| US5242942A (en) | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
| US5384327A (en) | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
| US6083969A (en) | 1999-10-20 | 2000-07-04 | Ortho-Mcneil Pharaceutical, Inc. | 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents |
| FR2800372B1 (fr) | 1999-11-03 | 2001-12-07 | Sanofi Synthelabo | Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant |
| FR2800375B1 (fr) | 1999-11-03 | 2004-07-23 | Sanofi Synthelabo | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
| US20020137802A1 (en) | 2000-09-28 | 2002-09-26 | Travis Craig R. | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| US7271189B2 (en) | 2003-10-20 | 2007-09-18 | Solvay Pharmaceuticals, Inc. | 1H-imidazole derivatives as cannabinoid receptor modulators |
| US7151097B2 (en) * | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
| JPWO2005063241A1 (ja) | 2003-12-26 | 2007-07-19 | 小野薬品工業株式会社 | ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤 |
| DK1735286T3 (da) | 2004-03-24 | 2012-04-02 | Janssen Pharmaceutica Nv | Tetrahydroindazoler som cannabinoidmodulatorer |
| FR2875230A1 (fr) | 2004-09-13 | 2006-03-17 | Sanofi Aventis Sa | Derives de pyrazole condense, leur preparation et leur application en therapeutique |
| ES2375213T3 (es) * | 2005-09-23 | 2012-02-27 | Janssen Pharmaceutica Nv | Moduladores de cannabinoides de hexadhidro-cicloheptapirazol. |
| DE602006012514D1 (de) * | 2005-09-23 | 2010-04-08 | Janssen Pharmaceutica Nv | Hexahydro-cyclooctyl-pyrazol-cannabinoid-modulatoren |
| US20070117857A1 (en) * | 2005-09-23 | 2007-05-24 | Fina Liotta | Substituted 3-amido-tetrahydro-indazolyl cannabinoid modulators |
-
2007
- 2007-03-20 US US11/688,552 patent/US8378117B2/en not_active Expired - Fee Related
-
2008
- 2008-03-06 KR KR1020097021528A patent/KR20100015602A/ko not_active Application Discontinuation
- 2008-03-06 BR BRPI0809037-8A patent/BRPI0809037A2/pt not_active IP Right Cessation
- 2008-03-06 AU AU2008229202A patent/AU2008229202A1/en not_active Abandoned
- 2008-03-06 CN CN200880016624A patent/CN101677557A/zh active Pending
- 2008-03-06 EP EP08731511A patent/EP2139328A4/en not_active Withdrawn
- 2008-03-06 WO PCT/US2008/056011 patent/WO2008115705A2/en active Application Filing
- 2008-03-06 CA CA002681468A patent/CA2681468A1/en not_active Abandoned
- 2008-03-06 MX MX2009010157A patent/MX2009010157A/es not_active Application Discontinuation
- 2008-03-06 JP JP2009554630A patent/JP2010529949A/ja active Pending
- 2008-03-06 NZ NZ579649A patent/NZ579649A/en not_active IP Right Cessation
- 2008-03-19 PE PE2008000509A patent/PE20090061A1/es not_active Application Discontinuation
- 2008-03-19 AR ARP080101147A patent/AR065799A1/es unknown
- 2008-03-19 CL CL200800799A patent/CL2008000799A1/es unknown
- 2008-03-19 TW TW097109566A patent/TW200901976A/zh unknown
- 2008-06-03 UA UAA200910591A patent/UA98487C2/ru unknown
-
2009
- 2009-09-15 IL IL200957A patent/IL200957A0/en unknown
- 2009-10-05 CO CO09109472A patent/CO6220909A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200901976A (en) | 2009-01-16 |
| UA98487C2 (en) | 2012-05-25 |
| KR20100015602A (ko) | 2010-02-12 |
| JP2010529949A (ja) | 2010-09-02 |
| AU2008229202A1 (en) | 2008-09-25 |
| BRPI0809037A2 (pt) | 2014-09-16 |
| CO6220909A2 (es) | 2010-11-19 |
| EP2139328A2 (en) | 2010-01-06 |
| US20080070968A1 (en) | 2008-03-20 |
| CL2008000799A1 (es) | 2008-09-26 |
| MX2009010157A (es) | 2009-10-12 |
| IL200957A0 (en) | 2010-05-17 |
| PE20090061A1 (es) | 2009-01-26 |
| WO2008115705A2 (en) | 2008-09-25 |
| CN101677557A (zh) | 2010-03-24 |
| EP2139328A4 (en) | 2010-07-07 |
| NZ579649A (en) | 2011-12-22 |
| CA2681468A1 (en) | 2008-09-25 |
| WO2008115705A3 (en) | 2009-01-15 |
| US8378117B2 (en) | 2013-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065799A1 (es) | Moduladores cannabinoides hexahidrocicloheptapirazol | |
| PE20081454A1 (es) | Derivados de pirazol como moduladores del receptor 5-ht2a de serotonina utiles para el tratamiento de los transtornos relacionados con dicho receptor | |
| CO6160260A2 (es) | Compuestos derivados de alquinil fenilo para tratar enfermedades y desordenes oftalmicos | |
| ES2477940T3 (es) | Imidazoles condensados y composiciones que los incluyen para el tratamiento de enfermedades parasitarias tales como por ejemplo malaria | |
| CR10138A (es) | 1h indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina | |
| AR048341A1 (es) | Moduladores cannabinoides de tetrahidro-indazol | |
| AR071385A1 (es) | Compuestos de 2-imino-3-metil pirrolopirimidinona sustituida con tiofenilo,composiciones farmaceuticas que los contienen,y uso de los mismos para el tratamiento de patologias asociadas con la proteina beta amiloide,tales como alzheimer y otros formas de demencia. | |
| AR066509A1 (es) | Derivados de tiazol, medicamentos que los contienen, proceso de preparacion y usos como moduladores de beta amiloide. | |
| EA201100210A1 (ru) | Аналоги пиридона и пиридазона как модуляторы gpr119 | |
| ECSP077163A (es) | Compuestos para el tratamiento de trastornos inflamatorios | |
| AR077975A1 (es) | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina | |
| PE20150230A1 (es) | Nuevos diazaespirocicloalcanos y azaespirocicloalcanos | |
| CL2013002194A1 (es) | Compuestos derivados de 1-(1-(quinazolin-2-il) o quinolin-2-il)metil-piperidina, 1-(naftalen-2-il)metil)-(piperidina o perhidro-azepina) y otros derivados de los mismos; su composicion farmaceutica; y uso como moduladores de la actividad de los receptores de s1p, en el tratamiento de esclerosis multiple, enfermedades autoinmunes, trastornos inflamatorios cronicos, asma, artritis, entre otras. | |
| ECSP077358A (es) | Antagonistas del receptor 2 de citocina quimioatrayente de dipiperidina sustituida | |
| PA8779901A1 (es) | Compuestos amino-heterocíclicos | |
| GT200600165A (es) | Derivados dihidrobenzofuranos y usos de los mismos | |
| CO7081155A2 (es) | Inhibidores de serina/treonina cinasa | |
| AR074304A1 (es) | Moduladores heterociclicos de gamma- secretasa | |
| ECSP088627A (es) | Compuestos para el tratamiento de trastornos inflamatorios | |
| NO20084489L (no) | Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet | |
| AR092809A1 (es) | 3,5-diaminopirazol como inhibidor de quinasa | |
| ATE467632T1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
| ECSP067044A (es) | Compuestos para el tratamiento de trastornos inflamatorios | |
| AR094735A1 (es) | Benzamidas sustituidas con actividad hacia receptores ep4 | |
| AR077534A1 (es) | Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |